A Phase 1, Multicenter, Open-Label Study of UB-VV111 in Combination with Rapamycin in Relapsed/Refractory CD19+ B-Cell Malignancies

嵌合抗原受体 离体 医学 慢性淋巴细胞白血病 T细胞 免疫学 癌症研究 白血病 体内 生物 免疫系统 生物技术
作者
Jacob Garcia,Christine Dehner,Jeffrey J Teoh,Wayne Wallis
出处
期刊:Blood [Elsevier BV]
卷期号:144 (Supplement 1): 1750.1-1750.1 被引量:21
标识
DOI:10.1182/blood-2024-208461
摘要

Background and Significance: Autologous, ex vivo-manufactured chimeric antigen receptor (CAR) T cells directed against CD19 have demonstrated clinical activity. These products have gained approvals in the relapsed/ refractory (R/R) setting in multiple B-cell malignancies (BCMs), including large B-cell lymphoma (LBCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). However, challenges in product availability due to limited manufacturing capacity, the need for apheresis and lymphodepletion, failure to prior ex vivo CAR T therapy, and the level of patient fitness needed to wait for and receive ex vivo autologous CAR T therapy all pose significant challenges to the field, presenting significant unmet clinical need. UB-VV111 is a third-generation, self-inactivating, replication-incompetent lentiviral vector (LVV) investigational drug product comprising an envelope with cocal virus fusion glycoprotein (cocal) and surface engineered with a membrane-bound multidomain fusion (MDF) protein. The MDF protein contains CD58, CD80, and anti-CD3 single-chain variable fragment (scFv) components that provide both T-cell tropism and activation signals thought to be critical for effective CAR T-cell generation. UB-VV111 is designed to generate CD19-directed CAR T cells in a patient, thus addressing the delivery limitations that exist for currently available autologous CD19-directed CAR T cell therapies. UB-VV111 is to be administered by either the intranodal (IN) or intravenous (IV) route of administration (ROA). Administration of UB-VV111 by either the IN or IV ROA is expected to transduce T cells to generate CAR T cells designed to bind to CD19 antigen to mediate cell killing and express the rapamycin-activated cytokine receptor (RACR) system which, in the presence of rapamycin, is designed to enhance specific expansion of transduced cells. Study Design and Methods: Study UB-VV111-01 (INVICTA-1, NCT06528301) is a first-in-human, global, multicenter, dose-finding study of UB-VV111 administered IN or IV +/- rapamycin in CAR-naïve and CAR-exposed subjects with R/R LBCL and CLL/SLL. Dose escalation will proceed independently for each ROA using a Bayesian optimal interval (BOIN) design. Confirmation of CD19 expression will be required for all subjects with prior CD19-directed therapy. Major eligibility criteria include adults with R/R LBCL/CLL/SLL following at least 2 lines of prior therapy who have standard organ function, measurable disease according to Lugano 2014 (LBCL) or iwCLL 2018 (CLL/SLL), ECOG 0 or 1, and no prior allogeneic transplant. Primary objectives include determining the safety profile, maximum tolerated/administered dose, and recommended Phase 2 dose of UB-VV111 +/- rapamycin. Secondary/exploratory objectives include measuring preliminary antitumor activity (magnitude and durability), as well as translational correlates of safety/efficacy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
YouY0123完成签到,获得积分10
刚刚
士兵许三多完成签到,获得积分10
刚刚
yibo完成签到,获得积分10
1秒前
月月完成签到,获得积分10
1秒前
巧克力手印完成签到,获得积分10
1秒前
alamo完成签到,获得积分10
1秒前
可靠的正豪完成签到,获得积分10
1秒前
echo完成签到,获得积分10
2秒前
你说得对发布了新的文献求助20
4秒前
米饭区完成签到 ,获得积分10
5秒前
haissem完成签到 ,获得积分10
5秒前
6秒前
sjw525完成签到,获得积分10
6秒前
BAEK完成签到 ,获得积分10
7秒前
7秒前
追寻的山晴完成签到,获得积分10
8秒前
852的应助被yy采纳,获得10
8秒前
ppp发布了新的文献求助10
10秒前
胜似闲庭信步完成签到,获得积分10
10秒前
Liii完成签到 ,获得积分10
10秒前
wei发布了新的文献求助10
11秒前
尊敬的驳完成签到,获得积分10
11秒前
JoJo完成签到,获得积分10
13秒前
star完成签到,获得积分10
16秒前
16秒前
小贾完成签到,获得积分10
17秒前
杀死周一完成签到,获得积分10
19秒前
tina酱完成签到 ,获得积分10
21秒前
zhangyiyang完成签到 ,获得积分10
21秒前
隐形骁完成签到,获得积分10
21秒前
22秒前
16601107082发布了新的文献求助10
23秒前
liuchang完成签到 ,获得积分10
23秒前
22336完成签到,获得积分0
23秒前
Lemenchichi完成签到,获得积分10
23秒前
老实的鑫磊完成签到,获得积分20
24秒前
会过期的凤梨完成签到 ,获得积分10
25秒前
hahaha完成签到 ,获得积分10
25秒前
wailwq完成签到 ,获得积分10
26秒前
26秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166570
求助须知:如何正确求助?哪些是违规求助? 9559581
关于积分的说明 21750904
捐赠科研通 7757397
什么是DOI,文献DOI怎么找? 3429170
关于科研通互助平台的介绍 2553530
邀请新用户注册赠送积分活动 2473923